VEXAS综合征中的骨髓增生异常
VEXAS综合征是一种影响老年男性为主的克隆性血液炎症性疾病,由UBA1体细胞突变引起,以系统性炎症和进行性骨髓衰竭为特征。约30%至50%的患者诊断为骨髓增生异常综合征(MDS),而未经选择的MDS患者中仅1%有UBA1突变。本文综述了VEXAS综合征中MDS的独特血液学缺陷、组织学与分子特征及治疗策略。
要点
- VEXAS综合征患者中MDS诊断率约30%–50%,而普通MDS患者UBA1突变仅约1%。
- UBA1功能丧失突变导致UBA1b表达下降,引发未折叠蛋白积累和内质网应激。
- VEXAS相关MDS具有独特的临床、实验室和形态学特征,诊断具有挑战性。
核心结论
- VEXAS相关MDS具有独特的临床、实验室和形态学特征,并具有预后意义。
研究设计与样本
- 综述,检索并汇总当前关于VEXAS综合征中MDS特征的文献。
主要发现
- VEXAS综合征由UBA1体细胞突变引起,最常见为M41错义变异,导致UBA1b表达下降和内质网应激。
- 患者表现为系统性难治性炎症,需长期糖皮质激素和靶向免疫抑制治疗。
- 进行性骨髓衰竭和血细胞减少是核心特征,MDS诊断率约30%–50%,而普通MDS患者UBA1突变仅1%。
关键数值与推荐
- VEXAS综合征患者中MDS诊断率约30%至50%。
- 未经选择的MDS患者中UBA1突变率约1%。
临床怎么用
- 对表现为系统性炎症伴血细胞减少的老年男性患者,应考虑VEXAS综合征并评估UBA1突变。
- VEXAS相关MDS的诊断需结合临床、实验室和形态学特征,并注意其预后意义。
- 去甲基化药物是潜在治疗策略之一,但需进一步评估反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
VEXAS (vacuoles, E1 enzyme, X linked, autoinflammatory, somatic) syndrome is a clonal hematoinflammatory disorder affecting older, predominantly male patients, characterized by systemic inflammation and progressive bone marrow failure. It is caused by somatic mutations in ubiquitin-activating enzyme E1 (UBA1), an X-linked gene, essential for initiating cellular ubiquitination. Loss-of-function mutations, most commonly M41 missense variants, lead to decreased expression of the cytoplasmic isoform, UBA1b, resulting in accumulation of misfolded proteins and activation of the endoplasmic reticulum stress pathway. Patients classically present with systemic and often refractory inflammation, requiring chronic glucocorticoid treatment and targeted immunosuppressive therapies. A central hallmark of this syndrome is progressive bone marrow failure and associated cytopenia, with a diagnosis of myelodysplastic syndromes (MDS) being reported in ∼30% to 50% of patients, whereas only 1% of unselected patients with MDS have UBA1 mutations. This review examines current literature on distinct MDS features reported in VEXAS syndrome. We first summarize the defects and alterations in the hematopoietic system from UBA1 mutations, including associated peripheral blood and bone marrow findings. Next, we describe the histologic and molecular characteristics of patients with VEXAS syndrome, with and without MDS, and review potential treatment strategies, including responses to hypomethylating agents. Finally, we highlight that VEXAS-associated MDS is a challenging diagnosis but one with unique clinical, laboratory, and morphologic features, including prognostic implications.
引用
- Patel BA, Calvo KR, Reichard KK, et al. Myelodysplasia in VEXAS syndrome. Blood Adv. 2026. PMID: 42284697. doi:10.1182/bloodadvances.2025018827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。